Having trouble accessing articles? Reset your cache.

Sofosbuvir: Completed Phase III enrollment

Gilead completed enrollment in the open-label Phase III ION-2 trial evaluating a once-daily, oral fixed-dose combination of 400 mg sofosbuvir plus 90 mg ledipasvir with ribavirin for 12 weeks

Read the full 294 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE